Cargando…

TP53 structural variants in metastatic prostatic carcinoma

Sequencing data have been instrumental in identifying oncogenic drivers in prostatic carcinoma and highlighting biomarkers that define aggressive disease. A review of a series of 30 primary and metastatic prostatic carcinomas clinically sequenced at our cancer genomics laboratory utilizing a targete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sirohi, Deepika, Devine, Patrick, Grenert, James P., van Ziffle, Jessica, Simko, Jeffry P., Stohr, Bradley A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6583940/ https://www.ncbi.nlm.nih.gov/pubmed/31216325 http://dx.doi.org/10.1371/journal.pone.0218618

Ejemplares similares

Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer
por: Zhang, Wensheng, et al.
Publicado: (2022)

Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma
por: Hamada, Kazuki, et al.
Publicado: (2023)

Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer
por: Zhou, Jie, et al.
Publicado: (2022)

Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability
por: Tam, Benjamin, et al.
Publicado: (2021)

Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer
por: Greenland, Nancy Y., et al.
Publicado: (2022)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TP53 variants in p53 signatures and the clonality of STICs in RRSO samples
por: Akahane, Tomoko, et al.
Publicado: (2022)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Significance of TP53 and immune-related genes to prostate cancer
por: Huang, Hang, et al.
Publicado: (2021)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Common genetic variants in the TP53 pathway and their impact on cancer
por: Barnoud, Thibaut, et al.
Publicado: (2019)

Emerging insights into ethnic-specific TP53 germline variants
por: Fischer, Nicholas W, et al.
Publicado: (2023)

Tracking sub-clonal TP53 mutated tumor cells in human metastatic renal cell carcinoma
por: Bousquet, Guilhem, et al.
Publicado: (2015)

Analysis of Tp53 Codon 72 Polymorphisms, Tp53 Mutations, and HPV Infection in Cutaneous Squamous Cell Carcinomas
por: Loeb, Keith R., et al.
Publicado: (2012)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Prognostic significance of TP53 alterations in breast carcinoma.
por: Andersen, T. I., et al.
Publicado: (1993)

TP53/MicroRNA Interplay in Hepatocellular Carcinoma
por: Pollutri, Daniela, et al.
Publicado: (2016)

A Novel Variant in the TP53 Gene Causing Li–Fraumeni Syndrome
por: Papadimitriou, Dimitrios T., et al.
Publicado: (2023)

Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222
por: Enciso-Mora, V, et al.
Publicado: (2013)

Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis
por: Kratz, Christian P., et al.
Publicado: (2021)

Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53
por: Omran, Meis, et al.
Publicado: (2020)

TP53 drives invasion through expression of its Δ133p53β variant
por: Gadea, Gilles, et al.
Publicado: (2016)

Somatic TP53 variants frequently confound germline testing results
por: Weitzel, Jeffrey N., et al.
Publicado: (2017)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
por: Kasherman, Lawrence, et al.
Publicado: (2021)

In cis TP53 and RAD51C pathogenic variants may predispose to sebaceous gland carcinomas
por: Le Duc, Diana, et al.
Publicado: (2020)

The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer
por: Otto, N, et al.
Publicado: (2012)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
por: Indeglia, Alexandra, et al.
Publicado: (2023)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
por: Köbel, Martin, et al.
Publicado: (2016)

TP53, SPOP and PIK3CA Genes Status in Prostate Cancer
por: Al Zoubi, Mazhar Salim, et al.
Publicado: (2020)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8uqimvohvceus6im2pkc482s1f